@JohnGritt concept conflation is often used to obscure wishful thinking. In this case, truly lowering the “cost,” —since the actual production cost of synthetic insulin is relatively de minimus here— would involve in turn tackling more complex issues like IP reform and lowering entry barriers for true competition. But with widespread insulin rationing among diabetics leading to a steady trickle of deaths, short term as well as long term fixes are called for.